[Solved] Psilocybin trip against Dyskeratosis congenita

Dyskeratosis congenita (DC) is a rare, hereditary disorder in which the body struggles to maintain healthy stem cells, partly due to genetic abnormalities in the telomerase system. Patients with DC typically have extremely short telomeres, which leads to accelerated aging of tissues such as the skin, nails, bone marrow, and lungs.

In the article Psilocybin against DNA aging and telomere protection It is described how psilocin (the active substance of psilocybin) helps cells maintain their telomeres. Through activation of the enzyme SIRT1, psilocybin indirectly stimulates the production of TERT, the active part of telomerase—the enzyme that lengthens telomeres. This mechanism is theoretically relevant for people with DC, where telomerase activity is actually deficient.

While this sounds promising, it is important to emphasize that the current findings are primarily based on laboratory research in cells and mice. For people with a genetic disorder like DC, the defects are often deeply embedded in the DNA. Psilocybin could theoretically optimize the function of remaining telomerase or reduce oxidative damage, but it will not correct the genetic cause of DC.

However, psilocybin may possibly contribute indirectly to better cell function, less inflammation, and improved psychological well-being.

A psilocybin session should therefore be placed at DC in a broader context of support — not as a treatment, but as a possible complementary approach. 

In short: psilocybin offers theoretical perspective for DC, particularly due to its effects on telomerase and DNA protection. However, for now, it remains an experimental, complementary approach that should only be considered under proper guidance.